 The performance of a drug in a specific clinical trial setting often does not coincide with the drug effect in daily clinical practice (efficacy-effectiveness gap, Eichler et al. 2011 ).  Behavior and biology could influence the variability of drug response (Eichler et al. 2011) . Part of the biological variability is due to genomics, extrinsic and intrinsic factors. The latter are e.g. age, sex, disease duration, baseline severity etc. (Falagas et al. 2010; Kirsch et al. 2008; van Staa et al. 2009 ).
 To systematically review and compare baseline (BL) characteristics of rheumatoid arthritis patients in published observational studies (OBS) and randomized controlled trials (RCT). 
B A C K G R O U N D R E F E R E N C E S

Review results:
We included 106 articles on OBSs and 41 articles on RCTs (see Figure 1 ).
Analysis results:
We found statistically significant differences in age, disease duration and number of prior DMARDs between RCTs and OBSs for all three drugs TCZ, RTX and ETN (see Figure 2 ). We also found the following statistically significant differences:  The mean DAS28 at BL for TCZ is 6. 
O B J E C T I V E M E T H O D S
In-and exclusion criteria + Diagnosis of RA + Adult patients
+ Study type (OBS or RCT) + Intervention Rituximab (RTX), Tocilizumab (TCZ) or Etanercept (ETN)
+ Outcomes: Disease activity score 28 (DAS28), health assessment questionnaire disability index (HAQ-DI), BL characteristics: age, sex, rheumatoid factor (RF), disease duration etc. − <30 patients in study arm
Data sources
We searched the EMBASE and MEDLINE databases and used EPPI -Reviewer 4 to identify relevant papers (2 independent reviewers).
Analysis methods
 We run a random-effects meta-regression applied on each baseline characteristic and drug with study design (RCT or OBS) as moderator, using the R package «metafor» for the analysis (Viechtbauer 2010).  We did F-tests on the coefficient of the moderator to decide on statistically significant differences in BL characteristics between RCTs and OBSs. We used 0.1 as level of significance.  We created forest plots for each baseline characteristic and drug.
R E S U LT S D I S C U S S I O N
 This is the first review investigating the baseline characteristics of RCTs and OBSs in patients suffering from rheumatoid arthritis.  Our review shows differences between patient characteristics in randomized controlled studies and the target population. These could modify the treatment effect (Stuart et al. 2011) and hereby contribute to a potential efficacy-effectiveness gap. Duplicates within data base N= 37 / 0
